Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05608343 · ClinicalTrials.gov registry record · Phase 3
This Study is to Assess the Efficacy of Difamilast Ointment in Mild to Moderate Atopic Dermatitis(AD)
A Phase 3 study, sponsored by Acrotech Biopharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 153
- Enrollment target
NCT05608343 is a Phase 3 study that has completed, run by Acrotech Biopharma. The registered enrollment target is 153 participants.
The verdict
NCT05608343, a Phase 3 study, has completed, sponsored by Acrotech Biopharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 153 participants
- Enrollment target
Study Summary
This is a Phase 3 Double Blind multi-center study conducted at 40 investigational sites in United States to assess the efficacy and safety of Difamilast Ointment 1% in subjects ≥2 years of age with mild to moderate atopic dermatitis.
Interventions
- DRUG Placebo
- DRUG Difamilast
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 153 participants |
| Start Date | 2022-10-01 |
| Est. Completion | 2023-10-27 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05608343
The ClinicalTrials.gov registry entry for NCT05608343 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 153 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Acrotech Biopharma, which has 24 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05608343 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05608343 about?
NCT05608343 is a clinical study titled "This Study is to Assess the Efficacy of Difamilast Ointment in Mild to Moderate Atopic Dermatitis(AD)". This is a Phase 3 Double Blind multi-center study conducted at 40 investigational sites in United States to assess the efficacy and safety of Difamilast Ointment 1% in subjects ≥2 years of age with mild to moderate atopic dermatitis.
What is the current status of trial NCT05608343?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 153 participants. The study started on 2022-10-01. Estimated completion is 2023-10-27.
What interventions are being tested in trial NCT05608343?
The interventions under investigation include: Placebo (DRUG), Difamilast (DRUG).
Who is sponsoring clinical trial NCT05608343?
This trial is sponsored by Acrotech Biopharma, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.